Nucleic acids, vectors, host cells, polypeptides, and uses thereof
OwnerEnrique Alvarez, Jacquelyn Kaye McEntire +2inventors
InventorsEnrique Alvarez, Jacquelyn Kaye McEntire, Rosamund Carol Smith, Eric Wen Su
Life of this patent
Estimating the term…
Abstract
The present invention provides nucleic acid sequences encoding novel human proteins. These novel nucleic acids are useful for constructing the claimed DNA vectors and host cells of the invention and for preparing the claimed recombinant proteins and antibodies that are useful in the claimed methods and medical uses.
Claims38
Isolated nucleic acid comprising DNA having at least an 90% sequence identity to nucleic acid selected from the group consisting of:
- (a) a DNA molecule encoding an LP226 polypeptide comprising the sequence of amino acid residues 1 or about 27 through 430, inclusive, of SEQ ID NO:2;
- (b) a DNA molecule encoding an LP233 polypeptide comprising the sequence of amino acid residues 1 or about 27 through 162, inclusive, of SEQ ID NO:4;
- (c) a DNA molecule encoding an LP236 polypeptide comprising the sequence of amino acid residues 1 or about 27 through 451, inclusive, of SEQ ID NO:6;
- and,
- (d) the complement of the DNA molecule of (a), (b), or (c).
An isolated nucleic acid molecule encoding an LP polypeptide comprising DNA that hybridizes to the complement of the nucleic acid sequence that encodes amino acids selected from the group consisting of:
- (a) from 1 or about 27 to 430 of SEQ ID NO:2;
- (b) from 1 or about 27 to 162 of SEQ ID NO:4;
- and,
- (c) from 1 or about 27 to 307 of SEQ ID NO:6.
An isolated nucleic acid molecule comprising DNA encoding a polypeptide scoring at least 90% positives when compared to the sequence of amino acid residues selected from the group consisting of:
- (a) amino acid residues 1 or 27 through 430 inclusive, of SEQ ID NO:2;
- (b) amino acid residues 1 or 27 through 162 inclusive, of SEQ ID NO:4;
- and,
- (c) amino acid residues 1 or 27 through 451 inclusive, of SEQ ID NO:6.
An isolated polypeptide comprising an amino acid sequence comprising at least about 90% sequence identity to the sequence comprising amino acid residues selected from the group consisting of:
- (a) amino acid residues 1 or about 27 through 430, inclusive, of SEQ ID NO:2;
- (b) amino acid residues 1 or about 27 through 162, inclusive, of SEQ ID NO:4;
- and,
- (c) amino acid residues 1 or about 27 through 451, inclusive, of SEQ ID NO:6.
An isolated LP polypeptide scoring at least 90% positives when compared to the sequence of amino acids selected from the group consisting of:
- (a) amino acid residues 1 or 27 through 430, inclusive, of SEQ ID NO:2;
- (b) amino acid residues 1 or 27 through 162, inclusive, of SEQ ID NO:4;
- and,
- (c) amino acid residues 1 or 27 through 451, inclusive, of SEQ ID NO:6.
A chimeric molecule comprising an LP polypeptide fused to a heterologous amino acid sequence.
An antibody which specifically binds to an LP polypeptide.
An agonist to an LP polypeptide.
An antagonist to an LP polypeptide.
A composition comprising a therapeutically effective amount of an active agent selected from the group consisting of:
- (a) an LP polypeptide, (b) an agonist to an LP polypeptide, (c) an antagonist to an LP polypeptide, and (d) an anti-LP antibody;
- in combination with a pharmaceutically acceptable carrier.
A method of treating a neurological disorder comprising administering a therapeutically effective amount of an LP agonist or antagonist to a mammal suffering from said disorder.
A method of treating a disorder requiring wound or tissue repair comprising administering a therapeutically effective amount of an LP agonist or antagonist to a mammal suffering from said disorder.
A method of treating a cardiovascular disorder comprising administering a therapeutically effective amount of an LP agonist or antagonist to a mammal suffering from said disorder.
A method of treating a proliferative disorder comprising administering a therapeutically effective amount of an LP agonist or antagonist to a mammal suffering from said disorder.
A method of treating a disorder associated with loss of bone mineral density comprising administering a therapeutically effective amount of an LP agonist or antagonist to a mammal suffering from said disorder.
A method of treating an osteopenia-related disorder comprising administering a therapeutically effective amount of an LP agonist or antagonist to a mammal suffering from said disorder.
A method of treating a fibrotic disorder comprising administering a therapeutically effective amount of an LP agonist or antagonist to a mammal suffering from said disorder.
Use of LP polypeptide in the manufacture of a medicament.
An article of manufacture comprising a container, label and therapeutically effective amount of an LP polypeptide, LP agonist, or LP antagonist in combination with a pharmaceutically effective carrier.
Dependencies are inferred from the claim text.